Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. McCloskey on the Efficacy of CPX-351 in FLT3-Mutated AML

September 15th 2022

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Fellows’ Passion Keeps Deol Sharp and Up to Date

September 14th 2022

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.

Dr. Verstovsek on Pemigatinib in FGFR1-Rearranged Myeloid Neoplasms

September 14th 2022

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Pemigatinib Represents Transformative Treatment for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

September 13th 2022

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12th 2022

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL

September 12th 2022

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Hodgkin Lymphoma Pioneer Saul A. Rosenberg, MD, FASCO, Dies at 95

September 8th 2022

Saul A. Rosenberg, MD, FASCO, the Maureen Lyles D’Ambrogio Professor Emeritus at Stanford School of Medicine and the 2019 Giants of Cancer Care® award winner for Lymphoma, died at the age of 95.

Azacitidine/Venetoclax Combo Delivers Promising Early Results in High-Risk CML, MDS

September 8th 2022

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

September 8th 2022

Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma

September 8th 2022

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.

Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations

September 7th 2022

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Investigators Set Sights on Optimizing CAR T-Cell Therapy in Lymphoma

September 4th 2022

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Daratumumab Compliance Rates in Multiple Myeloma Maintained in Real-World Analysis

September 2nd 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Fixed-Duration Bendamustine/Rituximab Is Beneficial Irrespective of Mutation Status in Waldenström Macroglobulinemia

September 2nd 2022

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.

Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL

September 2nd 2022

Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.

SEL24/MEN1703 Demonstrates Early Efficacy, Tolerability in R/R AML With IDH1/2 Mutations

September 1st 2022

The first-in-class dual PIM/FLT3 kinase inhibitor, SEL24/MEN1703, showcased encouraging efficacy and a tolerable safety profile in patients with acute myeloid leukemia whose tumors harbor a IDH1/2 mutation.

Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma

September 1st 2022

Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups

September 1st 2022

Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.

Future Directions in the Management of Immune Thrombocytopenia

September 1st 2022

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.